RCM Alert: Monsey Firm of Wohl & Fruchter Investigating Fairness of the Sale of R1 RCM to TowerBrook Capital Partners and Clayton, Dubilier & Rice

Core Viewpoint - Wohl & Fruchter LLP is investigating the fairness of R1 RCM, Inc.'s sale price of $14.30 per share to TowerBrook Capital Partners and Clayton, Dubilier & Rice, which is below the target prices set by Wall Street analysts [1][3]. Group 1: Sale Details - RCM agreed to be sold for $14.30 per share in cash, as recommended by a Special Committee of RCM's board of directors [3]. - As of March 28, 2024, TowerBrook already owned 35.7% of RCM's common stock [3]. Group 2: Analyst Price Targets - The sale price of $14.30 is below the target prices set by various Wall Street analysts, including: - $20.00 by Charles Rhyee of TD Cowen - $19.00 by Sean Dodge of RBC Capital - $18.00 by Vikram Kesavabhotla of Robert W. Baird - $18.00 by Glen Santangelo of Jefferies - $17.00 by Jack Wallace of Guggenheim - $17.00 by Michael Cherny of Leerink Partners [3]. Group 3: Investigation Focus - The investigation will assess whether the RCM Board of Directors acted in the best interests of shareholders, the independence of the Special Committee, the fairness of the agreed price, and the completeness of information disclosed regarding the transaction [3].